ReviewDrug design, development and therapy2026
Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo Performance.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperlipidemia is a major health concern worldwide, and oral therapies like statins, fibrates, and ezetimibe are severely limited by their poor water solubility, classified in the Biopharmaceutics Classification System (BCS) Class II. Although amorphous solid dispersion (ASD) technology shows promise in overcoming these biopharmaceutical limitations, a comprehensive synthesis linking molecular drug-polymer interactions to dissolution enhancement, pharmacokinetic performance, and preclinical in vivo efficacy remains underreported. Addressing this gap, this review comprehensively evaluates BCS Class II antihyperlipidemic ASD frameworks. A comprehensive literature search was conducted across PubMed, Scopus, ScienceDirect, and Google Scholar for studies published between 2015 and 2025 (n=16). ASD conversion significantly enhances dissolution kinetics via the "spring and parachute" mechanism. Specific molecular interactions, including hydrogen bonding and hydrophobic interactions with polymeric carriers, restrict molecular mobility and effectively inhibit recrystallization. Biopharmaceutical studies confirmed that these molecular pathways translate into improved systemic exposure in rodent dyslipidemia models, with significant increases in peak plasma concentration (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.